Robert Orlowski - Concepedia

Author

Robert Orlowski

Merck & Co., Inc., Rahway, NJ, USA (United States)ORCID

Also Known As

Hossein Borghaei, R Orlowski, R. Orlowski, R.J. Orlowski, Robert J Orlowski, Robert J. Orlowski, Robert Orlowski

Publications

2.3K

Citations

H-Index

Concepts

All Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)Eisai (United States)Memorial Sloan Kettering Cancer Center Saitama Medical University Hospital Clínico San Carlos

About

Robert Orlowski is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	837
2	Obstetrics	6	6	121
3	Health Sciences	3	3	715
4	Immunology	2	2	33
5	Cellular Therapies	1	1	21

Robert Orlowski

Publications

2.2K

Citations

H-Index

Page 1

	Year	Citations
A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma Alexander C. Huang, Robert Orlowski, Xiaowei Xu, Nature Medicine Neoadjuvant Pd-1 BlockadeSurgical OncologyMedicineMelanomaSingle Dose	2019	683
Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer Vicky Makker, Matthew H. Taylor, Carol Aghajanian, Journal of Clinical Oncology	2020	512
Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma Philippe Armand, Scott J. Rodig, Catherine Thiéblemont, Journal of Clinical Oncology	2019	256
Lenvatinib Plus Pembrolizumab in Previously Treated Advanced Endometrial Cancer: Updated Efficacy and Safety From the Randomized Phase III Study 309/KEYNOTE-775 Vicky Makker, Nicoletta Colombo, Antonio Casado, Journal of Clinical Oncology	2023	123
PD-L1 gene alterations identify a subset of diffuse large B-cell lymphoma harboring a T-cell–inflamed phenotype James Godfrey, Sravya Tumuluru, Riyue Bao, Blood	2019	120
Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma Payal D. Shah, Alexander C. Huang, Xiaowei Xu, Cancer Research Communications	2023	86
ENGOT-en11/GOG-3053/KEYNOTE-B21: a randomised, double-blind, phase III study of pembrolizumab or placebo plus adjuvant chemotherapy with or without radiotherapy in patients with newly diagnosed, high-risk endometrial cancer Toon Van Gorp, David Cibula, Weiguo Lv, Annals of Oncology	2024	64
First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial Christian Marth, Richard G. Moore, Mariusz Bidziński, Journal of Clinical Oncology	2024	45
A Phase Ib/II Study of Lenvatinib and Pembrolizumab in Advanced Endometrial Carcinoma (Study 111/KEYNOTE-146): Long-Term Efficacy and Safety Update Vicky Makker, Carol Aghajanian, Allen Lee Cohn, Journal of Clinical Oncology	2023	40
A multicenter, open-label, randomized, phase III study to compare the efficacy and safety of lenvatinib in combination with pembrolizumab versus treatment of physician's choice in patients with advanced endometrial cancer Vicky Makker, Nicoletta Colombo, Antonio Casado, Gynecologic Oncology Advanced Endometrial CancerGynecological SurgeryMedicineMetronomic TherapyGynecology	2021	39

Page 1